Related references
Note: Only part of the references are listed.Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer
Stephen J. H. Dobbin et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Common risk factors for heart failure and cancer
Wouter C. Meijers et al.
CARDIOVASCULAR RESEARCH (2019)
Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling
Riikka Kivela et al.
CIRCULATION (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PDGFR-β Signaling Regulates Cardiomyocyte Proliferation and Myocardial Regeneration
Zhang Yue et al.
CELL REPORTS (2019)
Role of c-Kit in Myocardial Regeneration and Aging
Fabiola Marino et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway
Yi Yang et al.
PHARMACEUTICAL BIOLOGY (2019)
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease
Arvind K. Pandey et al.
HYPERTENSION (2018)
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
Ashley Ghiaseddin et al.
ONCOLOGIST (2018)
VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes
Karla B. Neves et al.
HYPERTENSION (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events
Rhian M. Touyz et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
FLT3 inhibitors in acute myeloid leukemia
Mei Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Berberine Ameliorates High Glucose-Induced Cardiomyocyte Injury via AMPK Signaling Activation to Stimulate Mitochondrial Biogenesis and Restore Autophagic Flux
Weijian Hang et al.
FRONTIERS IN PHARMACOLOGY (2018)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
Jose Luis Zamorano et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition
Rhian M. Touyz et al.
HYPERTENSION (2017)
Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil
Manami Katoh et al.
INTERNATIONAL HEART JOURNAL (2017)
Assessing Microvascular Function in Humans from a Chronic Disease Perspective
Alfons J. H. M. Houben et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition
Timothy J. Stuhlmiller et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
Andreu Porta-Sanchez et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies
Matteo Santoni et al.
CANCER TREATMENT REVIEWS (2017)
Cancer Treatment-Induced Arrhythmias Focus on Chemotherapy and Targeted Therapies
Vitaly Buza et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2017)
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
Vivek Narayan et al.
CLINICAL CANCER RESEARCH (2017)
The Role of Angiogenesis in Cancer Treatment
Mehdi Rajabi et al.
BIOMEDICINES (2017)
miR-374 promotes myocardial hypertrophy by negatively regulating vascular endothelial growth factor receptor-1 signaling
Jong Sub Lee et al.
BMB REPORTS (2017)
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Husam Abdel-Qadir et al.
CANCER TREATMENT REVIEWS (2017)
Vascular Complications of Cancer Chemotherapy
Alan C. Cameron et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Sean A. Virani et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure
Yuri M. Lopatin et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors
Nicola Maurea et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection
Markus Rasanen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The therapeutic effect of bevacizumab on plaque neovascularization in a rabbit model of atherosclerosis during contrast-enhanced ultrasonography
Yang Li et al.
SCIENTIFIC REPORTS (2016)
Relation Between Cancer and Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study)
Wesley T. O'Neal et al.
AMERICAN JOURNAL OF CARDIOLOGY (2015)
Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape
Ammad Ahmad Farooqi et al.
CELL BIOCHEMISTRY AND FUNCTION (2015)
Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension
Francois Potus et al.
CIRCULATION (2015)
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Naomi B. Haas et al.
CLINICAL CANCER RESEARCH (2015)
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Etiology of angiogenesis inhibition-related hypertension
Stephanie Lankhorst et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy
Courtney K. Domigan et al.
JOURNAL OF CELL SCIENCE (2015)
Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension
Anna M. J. Thijs et al.
JOURNAL OF HYPERTENSION (2015)
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study
Manuela Quaresma et al.
LANCET (2015)
C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways
Bathri N. Vajravelu et al.
PLOS ONE (2015)
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
P. Ghatalia et al.
BRITISH JOURNAL OF CANCER (2015)
Bevacizumab and the Risk of Arterial and Venous Thromboembolism in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
Jai N. Patel et al.
CANCER (2015)
Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Selma F. Mohammed et al.
CIRCULATION (2015)
Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress
Stephanie Lankhorst et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Defective Angiogenesis Delays Thrombus Resolution A Potential Pathogenetic Mechanism Underlying Chronic Thromboembolic Pulmonary Hypertension
Sherin Alias et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
Heather Yvonne Small et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
Michael S. Ewer et al.
EUROPEAN JOURNAL OF CANCER (2014)
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
John F. Seymour et al.
HAEMATOLOGICA (2014)
Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression
Alexandra E. German et al.
JOURNAL OF CELL SCIENCE (2014)
VEGF Signals through ATF6 and PERK to Promote Endothelial Cell Survival and Angiogenesis in the Absence of ER Stress
Evdoxia Karali et al.
MOLECULAR CELL (2014)
Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer
Labib Imran Faruque et al.
PLOS ONE (2014)
Targeting the PDGF signaling pathway in tumor treatment
Carl-Henrik Heldin
CELL COMMUNICATION AND SIGNALING (2013)
PULMONARY HYPERTENSION ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
Manica Sodhi et al.
CHEST (2013)
Emerging Paradigms in Cardiomyopathies Associated With Cancer Therapies
Bonnie Ky et al.
CIRCULATION RESEARCH (2013)
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Devron R. Shah et al.
DRUG SAFETY (2013)
Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding
Irene M. Lang et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases
Jing Liang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2013)
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis - implications for cardiovascular safety
Stephan Winnik et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
Pierre Maison-Blanche et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension
Lin Piao et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis
Xing-Lin Chen et al.
PLOS ONE (2013)
Cardiomyocyte proliferation contributes to heart growth in young humans
Mariya Mollova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Philip S. Hall et al.
JACC-HEART FAILURE (2013)
Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
Nilka de Jesus-Gonzalez et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
Maria Abbondanza Pantaleo et al.
BMC CANCER (2012)
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
Iacopo Petrini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Coronary microvascular dysfunction in the clinical setting: from mystery to reality
Joerg Herrmann et al.
EUROPEAN HEART JOURNAL (2012)
Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
Mariette H. W. Kappers et al.
HYPERTENSION (2012)
Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes
Manuel Chiusa et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Aging Kit Mutant Mice Develop Cardiomyopathy
Lei Ye et al.
PLOS ONE (2012)
Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
Jiajie Zang et al.
PLOS ONE (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Molecular Signature of a Right Heart Failure Program in Chronic Severe Pulmonary Hypertension
Jennifer I. Drake et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2011)
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Mechanisms of Coronary Artery Spasm
Gaetano Antonio Lanza et al.
CIRCULATION (2011)
A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity
Hui Cheng et al.
CIRCULATION RESEARCH (2011)
Sorafenib-associated multivessel coronary artery vasospasm
T. Naib et al.
HERZ (2011)
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption
Stanislas Ropert et al.
INVESTIGATIONAL NEW DRUGS (2011)
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Reversibility of capillary density after discontinuation of bevacizumab treatment
N. Steeghs et al.
ANNALS OF ONCOLOGY (2010)
Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib
Astrid A. M. van der Veldt et al.
ANTI-CANCER DRUGS (2010)
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Javid Moslehi et al.
CIRCULATION (2010)
Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction
Lorena Zentilin et al.
FASEB JOURNAL (2010)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Overexpression of Vascular Endothelial Growth Factor 165 (VEGF165) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis
Tingting Chen et al.
JOURNAL OF CHEMOTHERAPY (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
A case of variant angina in a patient under chronic treatment with sorafenib
Italo Porto et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Conditional HIF-1α Expression Produces a Reversible Cardiomyopathy
Raffi Bekeredjian et al.
PLOS ONE (2010)
Role of VEGF in organogenesis
Jody J. Haigh
Organogenesis (2010)
Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
Lynette Pretorius et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
G. Di Lorenzo et al.
ANNALS OF ONCOLOGY (2009)
Apoptin, a tumor-selective killer
Marek Los et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis
M. Hennenberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway
Yang Zhou et al.
CARDIOVASCULAR RESEARCH (2009)
Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure
Harm J. Bogaard et al.
CIRCULATION (2009)
Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase
Risto Kerkela et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2009)
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire et al.
HYPERTENSION (2009)
Sorafenib-induced acute myocardial infarction due to coronary artery spasm
Yuichiro Arima et al.
JOURNAL OF CARDIOLOGY (2009)
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
T. Meyer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN Trial
Duncan J. Stewart et al.
MOLECULAR THERAPY (2009)
Evidence for Cardiomyocyte Renewal in Humans
Olaf Bergmann et al.
SCIENCE (2009)
Does Coronary Flow Trump Coronary Anatomy?
K. Lance Gould
JACC-CARDIOVASCULAR IMAGING (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Short hairpin RNA interference therapy for ischemic heart disease
Mei Huang et al.
CIRCULATION (2008)
Hypoxia-inducible factor-1 is central to cardioprotection -: A new paradigm for ischemic preconditioning
Tobias Eckle et al.
CIRCULATION (2008)
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
Neeltje Steeghs et al.
CLINICAL CANCER RESEARCH (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
The role of adherens junctions and VE-cadherin in the control of vascular permeability
Elisabetta Dejana et al.
JOURNAL OF CELL SCIENCE (2008)
Depressed Coronary Flow Reserve Is Associated With Decreased Myocardial Capillary Density in Patients With Heart Failure Due to Idiopathic Dilated Cardiomyopathy
Eleftheria P. Tsagalou et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells
Yvonne Will et al.
TOXICOLOGICAL SCIENCES (2008)
Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation
Dalit May et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma
M. Mego et al.
ANNALS OF ONCOLOGY (2007)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
c-kit dysfunction impairs myocardial healing after infarction
Massimo Cimini et al.
CIRCULATION (2007)
Autocrine VEGF signaling is required for vascular homeostasis
Sunyoung Lee et al.
CELL (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery
Wei Wei et al.
VASCULAR PHARMACOLOGY (2007)
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies
Hans-Peter Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Medical progress - Coronary microvascular dysfunction
Paolo G. Camici et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells
Yu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity
Patrick C. H. Hsieh et al.
CIRCULATION (2006)
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Betty Y. Y. Tam et al.
NATURE MEDICINE (2006)
Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines
Shafie Fazel et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload
Y Izumiya et al.
HYPERTENSION (2006)
Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis
I Friehs et al.
BASIC RESEARCH IN CARDIOLOGY (2006)
Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction
BB Ayach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Vascular endothelial growth factor in the lung
NF Voelkel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
VEGF-PLCγ1 pathway controls cardiac contractility in the embryonic heart
W Rottbauer et al.
GENES & DEVELOPMENT (2005)
Activation of p38 has opposing effects on the proliferation and migration of endothelial cells
ME McMullen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Direct intramyocardial plasmid vascular endothelial growth factor-A165-gene therapy in patients with stable severe angina pectoris -: A randomized double-blind placebo-controlled study:: The Euroinject One trial
J Kastrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload
IS Harris et al.
CIRCULATION (2004)
Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte
AYM Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway
P Kumar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis
O Yamaguchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Angiogenesis in health and disease
P Carmeliet
NATURE MEDICINE (2003)
Vascular endothelial growth factor in ischemia for vascular angiogenesis
TD Henry et al.
CIRCULATION (2003)
Progression from compensated hypertrophy to failure in the pressure-overloaded human heart -: Structural deterioration and compensatory mechanisms
S Hein et al.
CIRCULATION (2003)
Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure
H Arakawa et al.
HEART (2003)
Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation
MT Lin et al.
MOLECULAR PHARMACOLOGY (2003)
Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity
DL Brutsaert
PHYSIOLOGICAL REVIEWS (2003)
Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction
JI Nwogu et al.
CIRCULATION (2001)
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis
RM Tuder et al.
JOURNAL OF PATHOLOGY (2001)
Discovery of a novel Raf kinase inhibitor
JF Lyons et al.
ENDOCRINE-RELATED CANCER (2001)
Microcirculation in hypertension - A new target for treatment?
BI Levy et al.
CIRCULATION (2001)
Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function
FJ Giordano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Vascular endothelial growth factor enhances atherosclerotic plaque progression
FL Celletti et al.
NATURE MEDICINE (2001)
Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family
I Zachary et al.
CARDIOVASCULAR RESEARCH (2001)
Mechanisms of coronary angiogenesis in response to stretch:: role of VEGF and TGF-β
W Zheng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2001)
Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats
C Partovian et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)
The RET proto-oncogene in human cancers
SM Jhiang
ONCOGENE (2000)
Selective downregulation of VEGF-A165, VEGF-R1, and decreased capillary density in patients with dilative but not ischemic cardiomyopathy
D Abraham et al.
CIRCULATION RESEARCH (2000)
Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β
T Kandabashi et al.
CIRCULATION (2000)
The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal
M Le Gall et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
Share Paper
